Chemical & Synthetic Drugs

In the mobile internet era, the "smartphone-addicted" population continues to grow. This has led to an increasing number of eye diseases, with dry eye (keratoconjunctivitis sicca) being the most common chronic ocular surface disease. It is a multifactorial ophthalmic disease where abnormalities in the quality or quantity of different tear film components lead to reduced tear film stability, triggering different types of dry eye. Dry eye can cause various ocular discomfort symptoms or visual dysfunction. The global prevalence rate is 5%-34%, while in China it is 21%-30%. Currently, there are nearly 300 million dry eye patients in China.

Fondaparinux sodium is a synthetic anticoagulant drug approved by the FDA for the treatment and prevention of various venous and arterial thromboembolic disorders. It is clinically indicated for patients undergoing major orthopedic surgery of the lower extremities, such as hip fracture surgery, major knee surgery, or hip replacement surgery, to prevent venous thromboembolic events.

Legubixin is a novel anthracycline chemotherapeutic drug independently developed in China, and is a derivative of doxorubicin (also known as adriamycin). It is formed by conjugating a 6-maleimide group (EMC) with a tetrapeptide amino acid group (ALA-ALA-ASN-LEU), coupled to doxorubicin. The 6-maleimide group binds to albumin in plasma, forming a stable, non-toxic compound that reduces the drug's cardiotoxicity and damage to the immune system, while extending the drug's half-life in patients. Preclinical trials have confirmed that when Legubixin is combined with PD-1 inhibitors, the complete response rate can reach 7 times that of doxorubicin combined with PD-1 inhibitors.

Prostaglandins (PG) are a class of physiologically active unsaturated fatty acids, known as eicosanoids, widely present in mammals, marine coelenterates, and certain higher plants, playing important physiological regulatory functions. After binding to specific receptors, prostaglandins play key roles in mediating a series of cellular activities such as cell proliferation, differentiation, and apoptosis, as well as regulating female reproductive function and childbirth, platelet aggregation, and cardiovascular system balance.

Sugammadex Sodium, marketed under the brand name Bridion, was developed by Merck Sharp & Dohme and Organon. It represents the first major drug discovery in the field of anesthetics in nearly two decades, used to reverse the neuromuscular blockade induced by the routinely used neuromuscular blocking agents rocuronium and vecuronium. After postoperative injection, sugammadex sodium selectively and with high affinity encapsulates rocuronium, forming an inactive complex that is excreted via the kidneys, thereby reducing plasma levels of rocuronium and reversing neuromuscular blockade with favorable clinical outcomes. Sugammadex sodium is the world's first and only specific binding neuromuscular blocking reversal agent.